関連する実験動画

Updated: Oct 16, 2025

Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation

Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation

Published on: August 8, 2025

構造性心疾患のトランスキャセター手術を受けた患者の抗血栓治療

Paolo Calabrò^1,2, Felice Gragnano^1,2, Giampaolo Niccoli^3,4,5

¹Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli," Naples, Italy (P.C., F.G., E.M., A.C.).

|October 18, 2021

まとめ

トランスキャテーターの構造的な心臓の介入に対する抗血栓治療のバランスは複雑です. このレビューでは,これらの手順で出血のリスクを最小限に抑えながら,血栓を防ぐための証拠を強調しています.

科学分野:

心臓病科
介入心臓科
心血管医学

背景:

器具ベースのトランスキャテーターの介入は,構造的な心臓病のためにますます使用されています.
術には,大動脈弁の埋め込み,ミトラル/三弁の修復/埋め込み,左心房付属体の閉塞,門の閉塞が含まれます.
これらの介入は,血栓塞栓的事件を防ぐために抗血栓治療を必要とします.

研究の目的:

装置ベースのトランスキャセター介入に対する抗血栓療法に関する現在の証拠をレビューする.
血栓と出血のリスクのバランスをとるという課題を強調する.
特定の手順に基づく適合した抗血栓治療の必要性を強調する.

主な方法:

現代の証拠を体系的に検討する.
様々なトランスキャテーター構造的介入における抗血栓戦略の分析
治療に影響を与える臨床的徴候と手続的側面の議論

主要な成果:

抗血栓治療は不可欠ですが,出血のリスクがあります.
最適な抗血栓治療法は不明であり,手順に依存しています.
血栓や出血のリスクを管理するには個別的なアプローチが不可欠です

結論:

構造的な心臓病に対する装置ベースのトランスキャテーターの介入を支持する証拠があります
抗血栓治療の注意深い検討は,患者の結果を最適化するために不可欠です.
効果と安全性のバランスをとるには,適した抗血栓剤戦略が必要である.

キーワード:

抗凝固剤心房付属体心房細動フォアメン・オヴァル, 特許ミトラルバルブトロンボシストランスキャテーターによる大動脈弁の置換

さらに関連する動画

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

関連する概念動画

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Coronary Artery Disease V: Interprofessional Care

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

Acute Coronary Syndrome IV: Interprofessional Care

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...